Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Lung Cancer

Interventions

DRUG

Karelizumab+Apatinib

Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.

Trial Locations (1)

RECRUITING

Chengzhi Zhou, Guangzhou

All Listed Sponsors

lead

Zhou Chengzhi

OTHER